Erbitux TAILOR-Made For China First-Line mCRC Market, But Brand Recognition Merck’s Real Goal?

Merck's plans to penetrate the Chinese market further with its anti-EGFR cancer therapy Erbitux have received a boost with the Phase III TAILOR trial showing significant benefits when used first-line in metastatic colorectal cancer in this population.